Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ascending dose study of NE-180 in anemic cancer patients receiving chemotherapy
2007-002700-18Phase 2Active
- Sponsor
- Neose Technologies, Inc.
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycopegylated erythropoietin in cancer-associated anemia (CRA), sponsored by Neose Technologies, Inc. Primary endpoints: Haemoglobin response, Safety and tolerability and 2 more. Started Jul 2007; status: active.
02
Drugs
glycopegylated erythropoietin
03
Conditions
cancer-associated anemia (CRA)
Beyond the preview
Go deeper on 2007-002700-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002700-18.